Use of phosphodiesterase 5 inhibitor in preparation of medicament for resisting fibrotic diseases
A phosphodiesterase type 5 inhibitor is used in the preparation of a medicament for resisting fibrotic diseases. Experiments in animal models of ischemia-reperfusion (UIRI)-induced renal fibrosis, unilateral ureteral obstruction (UUO)-caused kidney fibrosis and idiopathic pulmonary fibrosis show that a PDE5 inhibitor such as tadalafil, sildenafil and vardenafil can significantly inhibit the expression of multiple fibrosis iconic proteins such as fibronectin, collagen I, renal injury molecule-1, and α-skeletal muscle actin in UIRI and UUO renal fibrosis lesions, improves glomerulopathy, degree of renal tubular distension, renal interstitial collagen fiber deposition and inflammatory cell infiltration, reduces the fibrotic area within the lesion, and significantly inhibits the progression of renal fibrosis; and the PDE5 inhibitor can significantly improve smooth muscle proliferation and inflammatory cell infiltration in bronchioles and pulmonary arterioles of idiopathic pulmonary fibrosis lesion, improve damage condition of alveolar tissue, and significantly inhibit the progression of pulmonary fibrosis.
1 . A pharmaceutical composition for treating a fibrotic disease, comprising a phosphodiesterase type 5 inhibitor and a pharmaceutically-acceptable auxiliary material or excipient,
wherein the fibrotic disease is renal fibrosis caused by renal ischemia reperfusion injury, and the phosphodiesterase type 5 inhibitor is a sildenafil analog
which is preferably in an oral, injection or atomized dosage form; or
wherein the fibrotic disease is renal fibrosis caused by ureteral obstruction, and the phosphodiesterase type 5 inhibitor is tadalafil, which is preferably in an oral, injection or atomized dosage form; or
wherein the fibrotic disease is idiopathic pulmonary fibrosis, and the phosphodiesterase type 5 inhibitor is tadalafil or sildenafil, which is preferably in an oral, injection or atomized dosage form.
2 . A method for treating a fibrotic disease, comprising administering a phosphodiesterase type 5 inhibitor to a subject in need thereof,
wherein the fibrotic disease is renal fibrosis caused by renal ischemia reperfusion injury, the phosphodiesterase type 5 inhibitor is a sildenafil analog
or wherein the fibrotic disease is renal fibrosis caused by ureteral obstruction, the phosphodiesterase type 5 inhibitor is tadalafil.
3 . The method according to claim 2 , wherein the sildenafil analog
is orally administrated at a dosage of 0.405 mg·kg −1 ·d −1 for 10 days.
4 . The method according to claim 2 , wherein the sildenafil analog
is administrated by injection at a dosage of 0.1215-0.162 ml·kg −1 ·d −1 for 10 days.
5 . The method according to claim 2 , wherein the tadalafil is orally administrated at a dosage of 0.081-0.81 mg·kg −1 ·d −1 for 7 days.
6 . The method according to claim 2 , wherein the tadalafil is administrated by injection at a dosage of 0.0243-0.324 ml·kg −1 ·d −1 for days.
7 . A method for treating a fibrotic disease, comprising administering a phosphodiesterase type 5 inhibitor to a subject in need thereof,
wherein the fibrotic disease is idiopathic pulmonary fibrosis, the phosphodiesterase type 5 inhibitor is tadalafil or sildenafil.
8 . The method according to claim 7 , wherein the tadalafil is orally administrated at a dosage of 0.81-3.24 mg·kg −1 ·d −1 for 14 days; or the sildenafil is orally administrated at a dosage of 3.24 mg·kg −1 ·d −1 for 14 days.
9 . The method according to claim 7 , wherein the tadalafil is administrated by injection at a dosage of 0.243-1.296 ml·kg −1 ·d −1 for 14 days; or the sildenafil is administrated by injection at a dosage of 0.972-1.296 ml·kg −1 ·d −1 for 14 days.